Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 P225 | DOI: 10.1530/endoabs.63.P225

1Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain; 2Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; 3Department of Neurosurgery, Hospital Universitario Ramón y Cajal, Madrid, Spain; 4Department of Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain; 5Department of Nuclear Medicine, Hospital Universitario Ramón y Cajal, Madrid, Spain; 6Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.


Background: Aggressive prolactinomas are rare neoplasms that are characterized by rapid growth and usually large tumor size, invasion of adjacent structures, an aggressive clinical behavior with little response to conventional treatment, high rate of recurrence, and elevated morbidity and mortality.

Case Report: 48-year-old woman diagnosed with life-threatening aggressive prolactinoma was referred to us for evaluation of complementary therapy after therapeutic failure to dopamine agonists (DA), several surgical interventions and radiotherapy. A clinical assessment by our multidisciplinary team recommended completing treatment with palliative surgery, DA, somatostatin analogues (SSA), temozolomide (TMZ), and re-irradiation. Two years after the last surgery the patient was well, without headaches showing postoperative changes in pituitary MRI, with normoprolactinemia and a partially empty sella without signs of tumor recurrence.

Conclusion: The present case demonstrates how multimodal treatment is effective and safe in the management of life-threatening aggressive prolactinoma.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.